Key Events This Week
28 Sep: New 52-week high at Rs.1,228.25
28 Sep: Sharp surge in derivatives open interest signalling bullish positioning
29 Sep: New 52-week high of Rs.1,232
30 Sep - 1 Oct: Consecutive declines, week closes at Rs.1,145.25 (-4.72%)
28 September: New 52-Week High and Bullish Derivatives Activity
On 28 September 2026, Zydus Lifesciences Ltd reached a new 52-week high of Rs.1,228.25, marking a significant milestone amid a broadly weak market. The stock closed at Rs.1,212.00, up 0.83% on the day, outperforming the Sensex which fell 1.60% to 34,788.97. This marked the fourth consecutive day of gains, with the stock appreciating 4.16% over this period.
Alongside the price surge, the derivatives market showed heightened activity. Open interest in Zydus Lifesciences derivatives rose sharply by 17.83%, with 4,587 additional contracts added, signalling increased bullish positioning. The combined futures and options turnover reached nearly ₹8,996 crores, reflecting strong liquidity and investor interest. The stock traded above all key moving averages, reinforcing the technical strength.
This bullish momentum was supported by a mojo grade upgrade to Buy on 22 September 2026 and a mojo score of 71.0, highlighting improved fundamentals and market sentiment.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
29 September: Fresh 52-Week High Amid Market Headwinds
Zydus Lifesciences continued its upward trajectory on 29 September, hitting a new 52-week high of Rs.1,232. The stock closed at Rs.1,195.20, down 1.39% from the previous day’s close, but still reflecting a 4.86% gain over the past five trading sessions. This performance was notable given the Sensex’s decline of 0.48% to 34,621.52 on the same day.
The stock’s technical positioning remained robust, trading above all major moving averages. Financially, the company maintained a strong profile with low leverage (debt-to-equity ratio of 0.05), healthy net sales growth of 13.79% annually, and operating profit growth of 19.95%. Return on equity stood at 17.49%, and return on capital employed was 21.8%, underscoring efficient capital utilisation.
However, some cautionary signals emerged from recent quarterly results, with a 35.0% decline in profit after tax and a dip in half-year ROCE to 19.13%. Despite these, the stock’s valuation remained fair with an enterprise value to capital employed ratio of 3.9 and a PEG ratio of 4.8.
30 September to 1 October: Correction Amid Broader Market Weakness
The final two trading days of the week saw a correction in Zydus Lifesciences’ share price. On 30 September, the stock declined 2.66% to Rs.1,163.35, followed by a further 1.56% drop on 1 October to close at Rs.1,145.25. These declines occurred alongside continued weakness in the Sensex, which fell 0.17% and 0.99% respectively on these days.
The stock’s weekly decline of 4.72% contrasted with the Sensex’s 3.20% fall, indicating a modest outperformance despite the downward trend. The correction may reflect profit-taking after the earlier rally and cautious sentiment given the broader market environment and recent moderation in financial metrics.
Get the full story on Zydus Lifesciences Ltd! Our detailed research dives into fundamentals, sector comparison, technical analysis, and valuations for this mid-cap. Make informed decisions!
- - Full research story
- - Sector comparison done
- - Informed decision support
Daily Price Performance vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-09-28 | Rs.1,212.00 | +0.83% | 34,788.97 | -1.60% |
| 2026-09-29 | Rs.1,195.20 | -1.39% | 34,621.52 | -0.48% |
| 2026-09-30 | Rs.1,163.35 | -2.66% | 34,564.37 | -0.17% |
| 2026-10-01 | Rs.1,145.25 | -1.56% | 34,221.41 | -0.99% |
Key Takeaways
Positive Signals: Zydus Lifesciences demonstrated resilience by outperforming the Sensex’s 3.20% decline with a smaller 4.72% fall despite a weak market. The stock’s ability to hit two consecutive 52-week highs early in the week reflects underlying strength and investor interest. The sharp surge in derivatives open interest and volume on 28 September indicates bullish market positioning and strong liquidity. The company’s solid fundamentals, including low debt, healthy sales and profit growth, and efficient capital utilisation, underpin its medium-term prospects.
Cautionary Signals: The latter part of the week saw a correction, possibly due to profit-taking and broader market weakness. Recent quarterly results showed a 35.0% decline in profit after tax and a dip in half-year ROCE, signalling some moderation in operational performance. Technical indicators, while largely positive, show mixed signals in some momentum measures. The stock’s valuation metrics, including a PEG ratio of 4.8, suggest the market is pricing in growth but also reflecting risk.
Conclusion
Zydus Lifesciences Ltd’s week was characterised by initial strength with new 52-week highs and robust derivatives market activity, followed by a correction amid a broadly weak Sensex. The stock’s outperformance relative to the benchmark highlights its relative resilience in a challenging environment. Strong fundamentals and improved mojo grade underpin the company’s quality, although recent financial moderation and mixed technical signals warrant cautious monitoring. Investors should watch for further developments in earnings and sector dynamics to assess the sustainability of the current momentum.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
